Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Week 45

November 2 – 8, 2026 · 6 articles

Clinical

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

Xu CR, Zhang Y, Lin G, et al.

Lancet (London, England)

The randomized phase 3 HERON-Lung01 trial evaluated the efficacy and safety of ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate (ADC), compared with platinum-pemetrexed chemotherapy in 498 patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who progressed on prior EGFR tyrosine kinase inhibitor (TKI) therapy. At the prespecified interim analysis, ruzaltatug rezetecan significantly prolonged progression-free survival compared to chemotherapy (median 8.3 months vs 5.4 months; HR 0.47; p < 0.0001). The safety profile was manageable, with grade 3 or higher treatment-related adverse events occurring in 41% vs 39% of patients, predominantly hematological, and leading to treatment discontinuation in only 1% per arm. These findings establish ruzaltatug rezetecan as a promising post-TKI therapeutic option in advanced EGFR-mutated NSCLC.

Clinical · Molecular biology

Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer

Fialkoff G, Takahashi N, Sharkia I, et al.

The Journal of clinical investigation

This study investigates the use of plasma nucleosome profiling (cfChIP-seq) to assess tumor burden and molecular subtypes in small cell lung cancer (SCLC). Researchers applied this technique to 441 plasma samples, integrating the profiles with matched tumor transcriptomes. The results demonstrate that cfChIP-seq captures the epigenetic and transcriptional landscape of SCLC, enabling non-invasive inference of transcriptional subtypes. A cfChIP-seq-derived score also tracked radiographic tumor burden and was associated with prognosis. This liquid biopsy platform offers potential for real-time monitoring and therapeutic stratification in SCLC.

Clinical · Molecular biology

Molecular underpinnings of metastatic small renal masses

Kapur P, Beshnova D, Zhong H, et al.

JCI insight

This study performed integrated morphological and molecular profiling, including whole-exome sequencing and RNA-Seq, on a multiinstitutional cohort of metastatic small renal masses (SRMs). The aim was to understand the molecular underpinnings of metastatic competence in these tumors, which are often managed with active surveillance. Researchers identified distinct genetic alterations in metastatic non-clear cell SRMs, such as NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs exhibited multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, along with co-occurring driver alterations in genes like BAP1 and mTOR pathway genes. Transcriptomic analyses revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function.

Clinical

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial

Vergote I, Cibula D, Powell M, et al.

The Lancet. Oncology

The phase 3 KEYLYNK-001 (ENGOT-OV43/GOG-3036) trial investigated the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance as first-line treatment for patients with advanced BRCA1/2 non-mutated epithelial ovarian cancer. The study randomized 1367 patients into three arms: pembrolizumab-olaparib, pembrolizumab alone, or placebo, all combined with initial chemotherapy. Results demonstrated a significant improvement in progression-free survival for the pembrolizumab-olaparib group compared to the control, both in the PD-L1 CPS ≥10 and intention-to-treat populations. This combination regimen suggests a potential new therapeutic option for this patient population.

Clinical

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

Demir N, Kıkılı Cİ, Kemik F, et al.

Lung cancer (Amsterdam, Netherlands)

This multicenter real-world study investigated histologic transformation to small-cell lung cancer (SCLC) in EGFR-mutant non-small cell lung cancer (NSCLC) patients, an aggressive resistance mechanism to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The study included 59 patients and found that adding immunotherapy (atezolizumab, durvalumab) to carboplatin and etoposide (CE) after transformation was associated with significantly improved post-transformation overall survival (17.0 months versus 9.0 months with CE alone). These findings suggest that immunotherapy may be beneficial in this setting, challenging prior evidence. Systematic re-biopsy is highlighted as crucial to confirm transformation and guide treatment.

Clinical · Molecular biology

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)

Kim HS, Zhang L, Bodor JN, et al.

Lung cancer (Amsterdam, Netherlands)

This study represents the largest to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving front-line osimertinib. Researchers analyzed data from patients within a U.S. clinical-genomic database. The findings indicated that the presence of either the EGFR L858R mutation or a TP53 co-mutation independently predicted inferior real-world progression-free survival (rwPFS) and overall survival (OS). Patients with both unfavorable alterations (EGFR L858R and mutant TP53) experienced the shortest survival, with a median rwPFS of 10.1 months and a median OS of 21.3 months. This risk stratification could assist in identifying patients who might benefit from novel trials or intensified therapies.